AbClon Inc.
Financials
Valuation Metrics
AbClon Inc.'s Market Cap is ₩5287B. At end of 2025 it was ₩8480B. Ranked #441 of 2,436 in KR market (top 18%), #155 of 1,649 on KOSDAQ (top 9%), #52 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 22%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 528.73B KRW | KR#441/2,436 Sec#52/234 |
| Revenue | 4.74B KRW | KR#2,348/2,436 Sec#198/234 |
| Net Income | -14.71B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 68.43B KRW | KR#2,001/2,436 Sec#170/234 |
| Net Assets | 58.28B KRW | KR#1,768/2,436 Sec#152/234 |
| Employees | 63 | KR#1,919/2,436 Sec#168/234 |
| Value | ||
| P/B | 9.07x | KR#2,333/2,436 Sec#208/234 |
| P/S | 111.65x | KR#2,391/2,436 Sec#212/234 |
| FCF Yield | -2.73% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -25.24% | KR#2,127/2,436 Sec#168/234 |
| ROA | -21.50% | KR#2,241/2,436 Sec#179/234 |
| Op. Margin | -315.38% | KR#2,361/2,436 Sec#198/234 |
| Revenue Growth | 5.22% | KR#1,152/2,436 Sec#107/234 |
| Financial Health | ||
| Debt Ratio | 117.43% | KR#599/2,436 Sec#78/234 |
| Total Debt | 7.00B KRW | KR#1,720/2,436 Sec#160/234 |
| FCF | -14.42B KRW | KR#1,815/2,436 Sec#166/234 |
| Cash | 36.11B KRW | KR#906/2,436 Sec#59/234 |
| Current Ratio | 4.89x | KR#299/2,436 Sec#56/234 |
| Performance | ||
| 1Y Return | 143.12% | KR#80/2,436 Sec#7/234 |
| 1M Return | -0.56% | KR#942/2,436 Sec#85/234 |
| From 52W High | -72.34% | KR#2,216/2,436 Sec#205/234 |
| 1Y MDD | -81.12% | KR#2,318/2,436 Sec#219/234 |
| Trading | ||
| Volume | 499,374 shares | KR#272/2,436 Sec#29/234 |
| Foreign Own. | 13.05% | KR#359/2,436 Sec#28/234 |
| Per Share | ||
| EPS | -742 KRW | KR—/2,436 Sec—/234 |
| BPS | 2,840 KRW | KR#1,846/2,436 Sec#145/234 |
Company Info
AbClon, established in 2010 and headquartered in Guro-gu, Seoul, is a bio-venture focused on antibody new drug development, manufacturing, and sales, specially listed on KOSDAQ in 2017. The company utilizes platforms such as NEST, AffiMab, and CAR-T, maintaining a research network with Atlas in Sweden. AbClon licensed AC101, developed with NEST technology, to Shanghai Henlius, and its CAR-T therapeutic AT101 is currently in Phase 2 clinical trials. It aims to strengthen its immune cell therapy presence through a partnership with Chong Kun Dang in 2025.